This edition of our newsletter begins with an article about a new study published in Gut, in which Prof Patrice Cani, Dr Anne Abot and Eve Wemelle identified novel intestinal bioactive compounds that could aid in the development of new antidiabetic drugs.
Next up, Dr Elena Verdu in collaboration with Dr Harry Sokol set out to investigate the microbial link between celiac disease dysbiosis and the altered aryl hydrocarbon receptor (AhR) pathway in celiac disease.
You will come across a new study that highlights the importance of diet in the development of Crohn’s disease by modulating inflammatory mechanisms. Plus, we are also featuring a recent study that provides new insights into enteric nervous system cells from both the mouse and human intestine.
Finally, a large observational study across 3400 individuals shows that, beyond interindividual variability, gut microbiome heterogeneity may play a role in individual responses to diet, lifestyle and medication.
The GMFH publishing team